Global Retinopathy Of Prematurity Therapeutics Market Analysis 2026

As per Cognitive Market Research's latest published report, the Global Retinopathy of Prematurity Therapeutics market size was $749.70 Million in 2024 and it is forecasted to reach $1,049.56 Million by the end of 2030. Retinopathy of Prematurity Therapeutics Industry's Compound Annual Growth Rate was 5.70% from 2024 to 2031.

What is Retinopathy of Prematurity Therapeutic?

Retinopathy of prematurity (ROP) is the abnormal development of blood vessels in the retina of the eye. It occurs in infants born prematurely. Retinopathy of prematurity is a bilateral disease of abnormal retinal neovascularization in preterm infants, especially those with the lowest birth weight. Retinopathy of prematurity (ROP) occurs when these blood vessels continue to grow in an abnormal pattern, forming bulges of tissue between the vascularized central retina and the non-vascularized peripheral retina.

Retinopathy of prematurity (ROP) usually affects infants weighing less than 100 grams. 1500g or more 30th week of gestation at birth, particularly for those with serious medical complications or those on excessive and prolonged oxygen therapy.  There are two ways to treat retinopathy in preterm infants. In severe retinopathy of prematurity, ablation of the peripheral anti-vascular retina by laser photocoagulation reduces the incidence of retinal folds and detachment. Another treatment is bevacizumab. Bevacizumab, a monoclonal antibody against vascular endothelial growth factor can stop the progression of retinopathy of prematurity. Compared with laser treatment, bevacizumab has a lower recurrence rate and fewer structural abnormalities in some cases.  Along with this, in freezing treatment (cryotherapy), the surgeon uses a freezing-cold instrument to terminate the part of the retina.

The increasing prevalence of eye disease along with the rise in R&D activities on medications for retinopathy of prematurity (ROP) from therapeutic companies is the major driving factor for the retinopathy of the prematurity therapeutics market during the forecast period. With limited resources for oxygen delivery and monitoring techniques, mature preterm infants are developing serious levels of ROP in developing countries. Therefore, anti-VEGF medications are now increasingly used to treat ROP. These drugs are inserted into the eye to stop unwanted blood vessel growth. For example, The National Eye Institute estimated that nearly 14,000–16,000 preterm infants in the USA annually have some symptoms of ROP. Annually, approximately 4001600 infants in the USA are blind from retinopathy of prematurity. 

Furthermore, the recent development of improved imaging techniques and the introduction of advanced technological infrastructure has led to the increased use of telemedicine and medical professionals are increasing the use of artificial intelligence to improve access to care for children at risk of developing ROP. Healthcare providers have shifted their focus from laser therapy to now having the choice of anti-vascular endothelial growth factor (VEGF) therapy for the further treatment of ROP. 

With the increasing incidence of ROP, there is a growing need for affordable and easy-to-use screening techniques for the appropriate identification of at-risk infants. Telemedicine for ROP is being implemented in many parts of the world, and artificial intelligence (AI) is now being explored as a means of improving access to care. Additionally, the telemedicine program has enabled the development of non-physician training programs and AI techniques for ROP diagnosis by collecting digital images captured during telemedicine sessions for use in training. All these factors are influencing the demand for the retinopathy of prematurity therapeutics market.